ALNYLAM PHARMACEUTICALS, INC.
ALNYNasdaq
$267.47
↓ -5.5%Jul 17 close · end-of-day
Price
1Y↓ -17.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$36.0B
Enterprise Value
$33.1B
P/E
114.8
P/S
9.7
P/B
45.6
EV/EBITDA
59.4
PEG
—
FCF Yield
1.3%
Dividend Yield
—
Revenue (TTM)
$3.7B
Net Income (TTM)
$313.7M
Free Cash Flow (TTM)
$465.4M
Gross Margin
—
Operating Margin
13.5%
Net Margin
8.5%
ROE
39.8%
ROIC
—
Debt / Equity
—
Net Cash
$2.9B
Return 1Y
-17.6%
Company profile
Alnylam Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS/ocular) diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
- CEO
- Yvonne L. Greenstreet
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 2,000
- Headquarters
- Massachusetts
- Website
- alnylam.com
Management & directors
- Mclaughlin MelissaChief Human Resources Officer
- Fitzgerald Kevin JosephCSO & EVP, Head of Research
- Garg PushkalEVP Chief R&D
- Greenstreet YvonneChief Executive Officer
- Poulton Jeffrey V.EVP, Chief Financial Officer
- Tanguler TolgaEVP, Chief Commercial Officer
- Supran BryanEVP, CLO and Secretary
Roles derived from SEC Form 4 filings.
Earnings
ALNY Q4 2025 Earnings
Period ends 2025-12-31
MetricActualYoY
Revenue$1.1B↑ +84.9%
Diluted EPS$1.14↓ -272.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $492.9M | $844.3M | $1.0B | $1.8B | $2.2B | $3.7B |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$828.4M | -$708.7M | -$785.1M | -$282.2M | -$176.9M | $501.6M |
| Net income | -$858.3M | -$852.8M | -$1.1B | -$440.2M | -$278.2M | $313.7M |
| Diluted EPS | -$7.46 | -$7.20 | -$9.30 | -$3.52 | -$2.18 | $2.33 |
| Operating cash flow | -$615.0M | -$641.7M | -$541.3M | $104.2M | -$8.3M | $524.1M |
| Free cash flow | -$685.3M | -$718.1M | -$613.3M | $41.9M | -$42.6M | $465.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -168.1% | -83.9% | -75.7% | -15.4% | -7.9% | 13.5% |
| Net margin | -174.1% | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% |
| Line item | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $494.3M | $659.8M | $500.9M | $593.2M | $594.2M | $773.7M | $1.2B | $1.1B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$43.4M | $48.6M | -$76.9M | -$105.2M | $18.1M | -$16.2M | $368.0M | $131.7M |
| Net income | -$65.9M | -$16.9M | -$111.6M | -$83.8M | -$18.3M | -$66.3M | $251.1M | $147.2M |
| Diluted EPS | -$0.52 | -$0.13 | -$0.87 | -$0.66 | -$0.14 | -$0.51 | $1.84 | $1.14 |
| Operating cash flow | -$81.5M | $124.2M | $43.7M | -$94.7M | -$118.3M | $153.7M | $325.1M | $163.6M |
| Free cash flow | -$94.5M | $116.1M | $39.5M | -$103.8M | -$127.3M | $139.4M | $313.0M | $140.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -8.8% | 7.4% | -15.4% | -17.7% | 3.0% | -2.1% | 29.5% | 12.0% |
| Net margin | -13.3% | -2.6% | -22.3% | -14.1% | -3.1% | -8.6% | 20.1% | 13.4% |
Company news
Jul 16, 2026
Jul 14, 2026
Jul 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-01 | PYOTT DAVID E I | Sale | 1,222 | $299.87 | $366,441.14 | filing |
| 2026-06-01 | PYOTT DAVID E I | Sale | 1,175 | $298.91 | $351,219.25 | filing |
| 2026-06-01 | PYOTT DAVID E I | Sale | 921 | $297.71 | $274,190.91 | filing |
| 2026-06-01 | PYOTT DAVID E I | Sale | 495 | $300.72 | $148,856.40 | filing |
| 2026-06-01 | PYOTT DAVID E I | Sale | 17 | $302.65 | $5,145.05 | filing |
| 2026-06-01 | PYOTT DAVID E I | Option exercise | 3,830 | $0.00 | $0.00 | filing |
| 2026-05-20 | HAMBURG MARGARET A | Award | 671 | $0.00 | $0.00 | filing |
| 2026-05-20 | BRANDICOURT OLIVIER | Award | 671 | $0.00 | $0.00 | filing |
| 2026-05-20 | Ausiello Dennis A | Award | 671 | $0.00 | $0.00 | filing |
| 2026-05-20 | Arbuckle Stuart A | Award | 671 | $0.00 | $0.00 | filing |
| 2026-05-20 | Sigal Charles Elliott | Award | 671 | $0.00 | $0.00 | filing |
| 2026-05-20 | SCHULMAN AMY W | Award | 838 | $0.00 | $0.00 | filing |
| 2026-05-20 | Reitan Colleen F | Award | 671 | $0.00 | $0.00 | filing |
| 2026-05-20 | PYOTT DAVID E I | Award | 671 | $0.00 | $0.00 | filing |
| 2026-05-20 | KELLOGG PETER N | Award | 671 | $0.00 | $0.00 | filing |
| 2026-05-13 | SCHULMAN AMY W | Option exercise | 11,250 | $70.20 | $789,750.00 | filing |
| 2026-04-06 | McLaughlin Melissa· Chief Human Resources Officer | Sale | 909 | $329.76 | $299,751.84 | filing |
| 2026-04-06 | McLaughlin Melissa· Chief Human Resources Officer | Sale | 829 | $330.46 | $273,951.34 | filing |
| 2026-04-06 | McLaughlin Melissa· Chief Human Resources Officer | Sale | 293 | $331.89 | $97,243.77 | filing |
| 2026-04-06 | McLaughlin Melissa· Chief Human Resources Officer | Sale | 199 | $333.94 | $66,454.06 | filing |
| 2026-04-06 | McLaughlin Melissa· Chief Human Resources Officer | Sale | 56 | $320.14 | $17,927.84 | filing |
| 2026-04-02 | McLaughlin Melissa· Chief Human Resources Officer | Sale | 359 | $317.44 | $113,960.96 | filing |
| 2026-04-02 | McLaughlin Melissa· Chief Human Resources Officer | Sale | 265 | $316.61 | $83,901.65 | filing |
| 2026-04-02 | McLaughlin Melissa· Chief Human Resources Officer | Sale | 245 | $322.86 | $79,100.70 | filing |
| 2026-04-02 | McLaughlin Melissa· Chief Human Resources Officer | Sale | 224 | $321.64 | $72,047.36 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.